Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans
-
- Tomosugi Naohisa
- Division of Aging Research, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University
-
- Yamamoto Shoko
- Central Research Institute, Jellice Co., Ltd.
-
- Takeuchi Masayoshi
- Division of AGEs Research, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University
-
- Yonekura Hideto
- Department of Biochemistry II, Kanazawa Medical University
-
- Ishigaki Yasuhito
- Division of Molecular Oncology and Virology, Department of Life Science, Medical Research Institute, Kanazawa Medical University
-
- Numata Noriaki
- Central Research Institute, Jellice Co., Ltd.
-
- Katsuda Shogo
- Department of Pathology II, President of Kanazawa Medical University
-
- Sakai Yasuo
- Central Research Institute, Jellice Co., Ltd.
この論文をさがす
抄録
<p>Aim: Collagen tripeptide (CTP) is a functional food with a high content of Gly-X-Y tripeptides derived from collagen. The objective of this study was to evaluate the effect of CTP administration on the development of atherosclerosis in healthy individuals.</p><p>Methods: The present study was conducted in the form of an open-label, single-dose trial for 6 months. All subjects ingested CTP twice daily: at breakfast and supper (total intake per day: 16 g). The effect of CTP on atherosclerosis was verified by measuring several indices, including serum lipid levels, toxic advanced glycation end-products (TAGE), and the cardio-ankle vascular index (CAVI), at baseline and 6 months.</p><p>Results: The low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol (HDL-C) ratio (LDL-C/HDL-C ratio) was significantly reduced in patients with an initial ratio of ≥2.5 (p=0.025). A significant reduction in TAGE was observed in all the subjects (p=0.031) and in the high-risk group (p=0.024). A significant reduction in CAVI was observed in all the subjects (right side: p=0.048, left side: p=0.047). As a result of multiple regression analysis, a significant relationship between the change in CAVI and that in each factor was not observed. No adverse events were observed during the study period.</p><p>Conclusions: The results of the present study indicate that CTP contributes to the prevention and treatment of atherosclerosis in healthy humans (UMIN000018525).</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 24 (5), 530-538, 2017
一般社団法人 日本動脈硬化学会